BioInsights - A closed, modular approach to autologous CAR T cell therapy manufacturing

A closed, modular approach to autologous CAR T cell therapy manufacturing

Cell & Gene Therapy Insights 2022; 8(8), 1045;

DOI: 10.18609/cgti.2022.154

Published: 20 September 2022
Jason Isaacson

Watch this video to gain an in-depth understanding of Thermo Fisher Scientific’s digitally compatible, GMP-compliant manufacturing platform to produce CAR T cells.

In this video you will see:

• Preparation of media and reagents used for cell isolation and activation
• Set up of consumable and instrument for cell processing using the Gibco CTS Rotea Counterflow Centrifugation System
• Isolation and activation of the cells using the Gibco CTS DynaMag Magnet and CTS Rotea System
• Transfer of the target cells to the bioreactor using the Thermo Scientific HyPerforma G3Lab controller for culture and lentiviral infection
• Bead removal, cell wash and concentrate and cryopreservation of the final CAR T cell product